POLR2A Drives Tumor Cell Aggressive in Both VHL and PBRM1 Mutation Renal-Cell Carcinoma

Linyan Chai, Zhengguo Qiu, Xiaozhi Zhang, Rong Li, Yao Wang, Kefeng WangResearch Square 2021 · DOI

TL;DR

Researchers have identified POLR2A as a critical "hub" protein that drives tumor aggression in clear cell renal cell carcinoma (ccRCC) following the loss of the tumor suppressors VHL and PBRM1. By silencing POLR2A, the team successfully arrested the cell cycle and inhibited tumor growth both in petri dishes and in animal models, marking it as a promising new therapeutic target.

What Problem Does This Paper Address?

Clear cell renal cell carcinoma (ccRCC) is the most common form of kidney cancer, often characterized by the loss of a specific region on chromosome 3p. This region houses several heavy-hitting tumor suppressor genes, most notably VHL and PBRM1.

While we know that losing these genes leads to more aggressive tumors, the clinical picture is complicated: VHL mutations alone don't always correlate with poor survival. This suggests there are "downstream" players—molecules that actually do the heavy lifting of driving tumor growth once the suppressors are gone. The authors of this study set out to find these "hub" molecules that could serve as vulnerabilities in the cancer's armor.

Methods

The study employed a "dry-to-wet" lab approach:

  1. Bioinformatics: The team analyzed mutational and transcriptional data from 539 ccRCC patients via The Cancer Genome Atlas (TCGA). They looked for genes that were significantly different between wild-type and mutant VHL/PBRM1 groups.
  2. Network Analysis: Using the STRING database, they constructed Protein-Protein Interaction (PPI) networks to identify "hub" proteins—those with the most connections and influence within the tumor's signaling pathways.
  3. In Vitro Validation: They used shRNA (short hairpin RNA) to "knock down" or silence POLR2A in two human kidney cancer cell lines (786-O and 769-P). They then measured cell viability (MTT assay), colony formation, and protein levels (Western Blot).
  4. In Vivo Validation: To see if the results held up in a living system, they injected the modified cancer cells into nude mice to observe tumor growth over 25 days.

Datasets

  • TCGA (The Cancer Genome Atlas): Specifically, the mutational and transcriptome (FPKM) data for 539 ccRCC patients.
  • STRING Database: Used for constructing and analyzing the protein-protein interaction networks.

Key Insights and Ideas

  • POLR2A as a Hub: Out of the top 100 differentially expressed genes, POLR2A emerged as a central hub. POLR2A is a major subunit of RNA polymerase II, the machinery responsible for synthesizing mRNA.
  • The Cell Cycle Connection: Gene Set Enrichment Analysis (GSEA) revealed that high POLR2A expression is tightly linked to pathways like E2F targets, G2M checkpoints, and mTOR1 signaling. Essentially, POLR2A keeps the "gas pedal" down on the cell cycle.
  • The Cyclin D1-CDK4 Axis: The researchers found that silencing POLR2A specifically reduced levels of Cyclin D1 and CDK4. These proteins are the gatekeepers of the G1 phase of the cell cycle; without them, the cancer cells cannot divide.
  • Proximity to TP53: Interestingly, the POLR2A gene is located very close to the TP53 gene (within 200 kb). The authors note that in other cancers, the loss of one often affects the other, creating a unique "collateral vulnerability" that can be exploited by specific inhibitors like $\alpha$-amanitin.

Key Results

  • Growth Inhibition: Knocking down POLR2A in the lab significantly reduced the ability of kidney cancer cells to form colonies and survive.
  • Tumor Reduction In Vivo: In the mouse xenograft models, the group with silenced POLR2A (shPOLR2A) showed a dramatic decrease in tumor weight (P < 0.01) and tumor volume (P < 0.001) compared to the control group.
  • Biomarker Reduction: Western blots confirmed that silencing POLR2A led to a decrease in PCNA (a marker for proliferation) and the cell cycle drivers CDK4 and Cyclin D1.

Limitations and Future Work

While the results are compelling, there are a few areas for further exploration:

  • Sample Size: The animal study used a relatively small cohort (n=4 per group). Larger studies would be needed to confirm these effects across more diverse genetic backgrounds.
  • Therapeutic Delivery: While silencing a gene with shRNA works in a lab, translating this into a human treatment is difficult. The authors mention $\alpha$-amanitin (a toxin that specifically inhibits POLR2A) as a potential drug, but its high toxicity means it would likely need to be delivered via sophisticated methods like antibody-drug conjugates (ADCs) or nanoparticles.
  • Clinical Correlation: Further research is needed to determine if POLR2A levels in human patients can accurately predict survival or response to existing treatments like mTOR inhibitors.

Summary updated

Abstract

<title>Abstract</title> <bold>Background:</bold> Loss of <italic>VHL </italic>always results in the loss of <italic>PBRM1 </italic>and causes aggressive clear cell renal cell carcinoma. However, <italic>VHL</italic> mutation was not significantly associated with worse survival, and PBRM1 modulate the tumor behavior is not clear. Thus, exploration of key molecules promoting the tumor aggressive is urgent in both <italic>VHL and PBRM1</italic> RCC patient.<bold>Methods and results: </bold>POLR2A was screened out by analyzing The Cancer Genome Atlas mutation data. Gene Set Enrichment Analysis results showed that E2F, G2M, and mTOR1 pathways were all altered in response to POLR2A high expression. Furthermore, In vitro, knockdown of POLR2A in 769-P and 786-O cells resulted in cell growth arrest and cell cycle blockade compared to control cells, the mechanism though decreasing cyclin D1-CDK4 axis. In vivo results were confirmed 786-O cells in which POLR2A expression was silenced, exhibited tumor growth inhibited compared to control group.<bold>Conclusions:</bold> POLR2A was the key protein after VHL and PBRM1 mutations in RCC, inhibition of POLR2A crippled cell viability and proliferation in vivo and in vitro, We anticipate POLR2A represents a novel candidate for RCC treatment.
BibTeX
@inproceedings{chai2021polr,
  author = {Linyan Chai and Zhengguo Qiu and Xiaozhi Zhang and Rong Li and Yao Wang and Kefeng Wang},
  title = {{POLR2A Drives Tumor Cell Aggressive in Both VHL and PBRM1 Mutation Renal-Cell Carcinoma}},
  booktitle = {Research Square},
  year = {2021},
  doi = {10.21203/rs.3.rs-1039666/v1},
}
Figure